Comparative Pharmacology
Head-to-head clinical analysis: ALTRENO versus SOTRET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTRENO versus SOTRET.
ALTRENO vs SOTRET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; believed to involve reduction of hepatic glucose production and improvement of insulin sensitivity via AMPK activation.
Binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene transcription to reduce sebum production, normalize follicular keratinization, and inhibit Propionibacterium acnes growth.
ALTRENO is not a recognized drug. No data available.
Oral isotretinoin 0.5-1 mg/kg/day divided twice daily for 15-20 weeks.
None Documented
None Documented
Terminal elimination half-life is 20-30 hours; steady state reached in 5-7 days.
Clinical Note
moderateIsotretinoin + Estrone sulfate
"The therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Estramustine
"The therapeutic efficacy of Estramustine can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Dienogest
"The therapeutic efficacy of Dienogest can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Medroxyprogesterone acetate
Terminal elimination half-life: 18-20 hours in adults; steady-state achieved after 5-7 days of dosing.
Primarily renal (70-80% as unchanged drug), with 10-15% biliary/fecal elimination.
Primarily hepatic metabolism with renal excretion of metabolites (approximately 60-80% in urine) and fecal elimination (15-30%).
Category C
Category C
Retinoid
Retinoid
"The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Isotretinoin."